Science + Possibilities
Pioneering Endocannabinoid-Based Drug Discovery
Our goal is to become a global leader in the development of safe and effective prescription medicines targeting the endocannabinoid system, with a particular focus on chronic pain.
Our Mission
We want to help people living with debilitating conditions by developing non-addictive pain medications to reduce the reliance on opioids.
Established in 2017, we are a biotech company focused on developing prescription medicines through a regulatory pathway, with a particular emphasis on targeting chronic pain. These are debilitating conditions where people may find themselves addicted to opioids, experiencing severe side effects or finding their treatments don’t work anymore. It is a market valued at nearly US$60bn and expected to rise to US$75bn by 2027. Our aim is to develop non-addictive prescription medicines to meet this huge need.
Through our innovative portfolio we aim to leverage the power of our library of proprietary pharmaceutical compounds to deliver medicines that will be first in class or have exclusivity in the market.
Our People
With experience across pharmaceutical operations, R&D, intellectual property, law and finance, our team has a track record of commercial and clinical excellence and a history of over 20 regulatory approvals for new medicines in the US and the EU. Together, our team is passionate about delivering breakthrough therapies for debilitating conditions.
